|
KMID : 1142020210560040279
|
|
Blood Research
2021 Volume.56 No. 4 p.279 ~ p.284
|
|
|
Treatment of adult Burkitt lymphoma with the CALGB 1002 protocol: a single center experience in Jordan
|
|
Ma’koseh Mohammad
Amarin Rula
Tamimi Faris
Sharaf Baha’
Abufara Alaa
Shahin Omar
Manassra Mohammed K. M.
Halahleh Khalid
|
|
|
Abstract
|
|
|
Background: The treatment of adult Burkitt lymphoma with pediatric-based chemotherapy protocols usually results in high cure rates, although with significant toxicity. We report our experience with the Cancer and Leukemia Group B1002 (CALGB 1002) protocol.
Methods: The files of adult patients diagnosed with Burkitt lymphoma and treated with the CALGB 1002 protocol at King Hussein Cancer Center between 2008 and 2017 were reviewed. Baseline demographics, clinical laboratory features, treatment details, and responses were collected. The correlations between clinical and laboratory variables with event-free survival (EFS) and overall survival (OS) were determined by univariate and multivariate analyses using backward stepwise Cox regression models. EFS and OS were plotted using Kaplan?Meier curves.
Results: This study included 19 patients with a median age of 33 years (range, 19?65). Eleven (58%) and two (10.5%) patients had advanced-stage and central nervous system disease, respectively. Among 106 administered cycles, the median interval between cycles was 23 days (range, 19?84 days). Sixteen patients (84%) achieved a complete response. After a median follow-up of 40.8 months, the 3-year EFS and OS rates were 78.95%. Patients with a low-risk International Prognostic Index (IPI) had better survival than those with intermediate-or high-risk IPI. Grade III?IV hematological toxicities occurred in 88% of patients, while 73% had grade III?IV mucositis.
Conclusion: In adult Burkitt lymphoma, the CALGB 1002 protocol provides high cure rates and can be administered promptly, but is associated with significant toxicity. Risk-adapted approaches and other, less toxic, chemotherapeutic regimens should be considered.
|
|
|
KEYWORD
|
|
|
Burkitt lymphoma, CALGB 1002, International Prognostic Index
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|